Lucy Elizabeth Kershaw1, David Lilburn1, Maurits Jansen1, Pilar Jimenez-Royo2, Antonella Napolitano Rosen2, Philip Murphy2, Alexandra Morgan2, Rob Janiczek2, Shareen Forbes3,4, and Scott Semple1,4
1Edinburgh Imaging, The University of Edinburgh, Edinburgh, United Kingdom, 2Experimental Medicine Imaging, GlaxoSmithKline, London, United Kingdom, 3Endocrinology Unit, The University of Edinburgh, Edinburgh, United Kingdom, 4BHF/University of Edinburgh Centre for Cardiovascular Sciences, The University of Edinburgh, Edinburgh, United Kingdom
Synopsis
Type 1 diabetes mellitus results in autoiummune destruction
of β-cells in the pancreas, which are responsible for insulin
production. Paramagnetic Mn2+
ions are taken up by β-cells as a calcium analogue and
could be used as an MR contrast agent to monitor β-cell function and therefore treatment
or disease progression in these patients.
Three manganese-based contrast agents (MnCl2, mangafodipir
and Mn gluconate) were used to measure pancreas enhancement after saline and
glucose challenge in healthy rats. All agents
showed greater enhancement after glucose challenge, with no marked difference
between the two agents that have been used clinically.
Introduction
Type 1 diabetes mellitus is an autoimmune
disease that results in destruction of insulin-producing β-cells within the pancreas [1]. A
non-invasive method for detection of β-cells would be valuable in these patients as a
method for monitoring disease progression or treatment response, since there is
evidence of remaining β-cell function in
some subjects who could, therefore, benefit from therapeutic intervention [2].
Manganese ions (Mn2+) are strongly paramagnetic, and have
been used in MR contrast agents since the 1980s [3]. In the pancreas, Mn2+ ions can act as a calcium analogue and enter
β-cells through
voltage-gated calcium channels [4]. T1
enhancement with MnCl2 has therefore been proposed as a method for
evaluating β-cell mass and
function in mice [5–8]. In
humans, one study has investigated Mn-enhanced MRI in diabetic patients [9], which showed that manganese-enhanced imaging
could be used to distinguish normoglycaemic from type 2 diabetic patients, characterised by relative insulin deficiency and diminished beta cells. Further work in this area has been limited by
a lack of clinically available Mn-based contrast agents. Recently, two Mn agents have become available
again for human use; mangafodipir (TeslaScan, IC Targets, Norway) and Mn gluconate
(SeeMore, Eagle Vision Pharmaceutical, USA).
In this work both contrast agents, as well as MnCl2 were used
to image the pancreas of healthy rats subjected to saline and glucose
challenges. The aim was to examine
whether Mn gluconate produces pancreatic enhancement similar to that seen with mangafodipir
(the agent used in the previous human study) [9] as a first step towards applying this contrast
agent in patients with type 1 diabetes mellitus and potentially type 2 diabetes.Methods
All animal studies were ethically reviewed and carried out
in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy
on the Care, Welfare and Treatment of Animals.
Rats were imaged in two sessions 1-2 weeks (mean 8.8 days) apart, during
administration of a saline (control) or glucose challenge and a manganese-based
contrast agent: MnCl2 (6 rats), mangafodipir (5 rats), Mn gluconate
(7 rats).
Images were acquired at 7 T (Agilent Technologies, Santa
Clara, USA) using a volume coil.
Cardiac, respiratory and temperature monitoring continued throughout the
scan session. Imaging included anatomical
T1w and T2w multislice TSE used to plan a coronal respiratory-gated
2D dynamic T1w gradient echo acquisition through the pancreas (TR=100
ms, TE=1.35 ms, α=60°, slice thickness=2 mm, matrix=128x128,
FOV=60 mm). After ~10 dynamic images the
challenge (2 ml/kg saline or 50% glucose) was injected using a syringe driver over
1 minute, followed after 2 minutes by the contrast agent injection (MnCl2
100 mmol/kg, mangafodipir 125 mmol/kg due to 80% dechelation [10], Mn gluconate 100 mmol/kg,
each injected over 20 minutes). Dynamic
imaging continued for 40 minutes after the Mn injection was complete, making a
total of approximately 60 minutes (140-180 frames).
The pancreas and a large ROI in the liver avoiding obvious
vessels were manually outlined on the dynamic images using anatomical images as
a guide. Mean enhancement curves were
plotted and a sigmoid function was fitted to each curve to calculate a plateau
enhancement value over baseline [5], including parameter uncertainty
from the fit covariance matrix. Plateau
height for the pancreas was normalised to that for liver, and compared for
glucose vs saline challenge.Results
One rat died in an early experiment where the
MnCl2 was infused over 10 minutes, leading to the 20 minute infusion
used for all subsequent experiments.
Five rats were removed from analysis due to technical issues with the
injections or imaging, leaving 12 complete datasets (3 MnCl, 5 mangafodipir, 4 Mn
gluconate). Figure 1 shows example
images, enhancement curves and fits from one subject. Fig. 2 shows sigmoid fit plateau height
within the pancreas normalised to that from the liver for saline and glucose
challenges for each rat. For saline vs
glucose challenge, mean increase in plateau height ± sd were: 22±18% for MnCl2,
31±29% for mangafodipir and 41±17% for Mn gluconateConclusion
All
three contrast agents produced similar enhancement, with greater plateau height
under glucose challenge in all but one case.
Following on from successful previous studies in diabetic mice, both
agents available for use in humans show potential for translation into a
clinical study investigating beta cell imaging of the pancreas in type 1
diabetes mellitus and potentially type 2 diabetes.Acknowledgements
We would like to thank Ross Lennen for assisting with the
animal experiments and Pat Antkowiak for helpful discussions regarding image
analysis.References
[1] G.C.
Weir, S. Bonner-Weir, A. Sharma, Regulation of Insulin Secretion and Islet Cell
Function, in: J. Skyler (Ed.), Atlas Diabetes Fourth Ed., Springer US, Boston,
MA, 2012: pp. 1–17. doi:10.1007/978-1-4614-1028-7_1.
[2] R.A.
Oram, A.G. Jones, R.E.J. Besser, B.A. Knight, B.M. Shields, R.J. Brown, A.T.
Hattersley, T.J. McDonald, The majority of patients with long-duration type 1
diabetes are insulin microsecretors and have functioning beta cells,
Diabetologia. 57 (2014) 187–191. doi:10.1007/s00125-013-3067-x.
[3] M.H.
Mendonca-Dias, E. Gaggelli, P.C. Lauterbur, Paramagnetic contrast agents in
nuclear magnetic resonance medical imaging., Semin. Nucl. Med. 13 (1983)
364–376.
[4] S.
Dryselius, E. Grapengiesser, B. Hellman, E. Gylfe, Voltage-dependent entry and
generation of slow Ca2+ oscillations in glucose-stimulated pancreatic
beta-cells., Am. J. Physiol. 276 (1999) E512-8.
http://www.ncbi.nlm.nih.gov/pubmed/10070018.
[5] P.F.
Antkowiak, S.A. Tersey, J.D. Carter, M.H. Vandsburger, J.L. Nadler, F.H.
Epstein, R.G. Mirmira, Noninvasive assessment of pancreatic β-cell function in
vivo with manganese-enhanced magnetic resonance imaging, Am. J. Physiol. -
Endocrinol. Metab. 296 (2009) E573-8. doi:10.1152/ajpendo.90336.2008.
[6] P.F.
Antkowiak, M.H. Vandsburger, F.H. Epstein, Quantitative pancreatic β-cell MRI
using manganese-enhanced Look-Locker imaging and two-site water exchange
analysis, Magn. Reson. Med. 67 (2012) 1730–1739. doi:10.1002/mrm.23139.
[7] P.F.
Antkowiak, B.K. Stevens, C.S. Nunemaker, M. McDuffie, F.H. Epstein,
Manganese-enhanced magnetic resonance imaging detects declining pancreatic
β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes,
Diabetes. 62 (2013) 44–48. doi:10.2337/db12-0153.
[8] A.
Meyer, K. Stolz, W. Dreher, J. Bergemann, V. Holebasavanahalli Thimmashetty, N.
Lueschen, Z. Azizi, V. Khobragade, K. Maedler, E. Kuestermann,
Manganese-Mediated MRI Signals Correlate With Functional β-Cell Mass During
Diabetes Progression, Diabetes. 64 (2015) 2138–2147. doi:10.2337/db14-0864.
[9] D.
Botsikas, S. Terraz, L. Vinet, S. Lamprianou, C.D. Becker, D. Bosco, P. Meda,
X. Montet, Pancreatic magnetic resonance imaging after manganese injection
distinguishes type 2 diabetic and normoglycemic patients, Islets. 4 (2012)
243–248. doi:10.4161/isl.20857.
[10] K.G.
Toft, S.O. Hustvedt, D. Grant, I. Martinsen, P.B. Gordon, G.A. Friisk, A.J.
Korsmo, T. Skotland, Metabolism and pharmacokinetics of MnDPDP in man, Acta
Radiol. 38 (1997) 677–689.